Progyny, Inc. Proceeds from Lines of Credit
Progyny, Inc. (PGNY) reported Proceeds from Lines of Credit of $182.03 million for the 12-month period ending 2019-12-31, per its 10-K filed 2022-03-01.
Discontinued › Cash Flow › Financing Activities
us-gaap:ProceedsFromLinesOfCredit · last filed 2022-03-01
- Progyny, Inc. proceeds from lines of credit for the quarter ending 2019-12-31 was $24.18M, a 17.82% decline year-over-year.
- Progyny, Inc. proceeds from lines of credit for the quarter ending 2019-09-30 was $63.09M.
- Progyny, Inc. proceeds from lines of credit for the quarter ending 2019-06-30 was $53.45M.
- Progyny, Inc. proceeds from lines of credit for the quarter ending 2019-03-31 was $41.31M.
- Progyny, Inc. proceeds from lines of credit for fiscal 2019 was $182.03M, a 182.56% increase from fiscal 2018.
- Progyny, Inc. proceeds from lines of credit for fiscal 2018 was $64.42M.
| Period end | Proceeds from Lines of Credit 3 month | Proceeds from Lines of Credit 6 month | Proceeds from Lines of Credit 9 month | Proceeds from Lines of Credit 12 month |
|---|---|---|---|---|
| 2019-12-31 | $24.18M derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-01 | $87.27M derived: sum of 2 quarters · filed 2022-03-01 | $140.72M derived: sum of 3 quarters · filed 2022-03-01 | $182.03M 10-K · filed 2022-03-01 |
| 2019-09-30 | $63.09M derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-06 | $116.54M derived: sum of 2 quarters · filed 2020-11-06 | $157.85M 10-Q · filed 2020-11-06 | $187.27M derived: sum of 4 quarters · filed 2021-03-01 |
| 2019-06-30 | $53.45M derived: 10-Q 6 month − 10-Q 3 month · filed 2020-08-07 | $94.76M 10-Q · filed 2020-08-07 | $124.17M derived: sum of 3 quarters · filed 2021-03-01 | |
| 2019-03-31 | $41.31M 10-Q · filed 2020-05-14 | $70.73M derived: sum of 2 quarters · filed 2021-03-01 | ||
| 2018-12-31 | $29.42M derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-01 | $64.42M 10-K · filed 2021-03-01 | ||
| 2018-09-30 | $35.00M 10-Q · filed 2019-12-06 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| agilon health, inc. (AGL) | United States | $1.272B | -7.76 |
| VIEMED HEALTHCARE, INC. (VMD) | United States | $0.336B | 29.92 |
| Park Dental Partners, Inc. (PARK) | United States | $0.094B | |
| BioRestorative Therapies, Inc. (BRTX) | United States | $0.064B | |
| CRYO CELL INTERNATIONAL INC (CCEL) | United States | $0.033B | -11.02 |
| MANGOCEUTICALS, INC. (MGRX) | United States | $0.010B | -0.43 |
| Sotera Health Co (SHC) | United States | $5.271B | 30.96 |
| DAVITA INC. (DVA) | United States | $11.147B | 16.80 |